SEC Form 4 Ingestion•Corporate Insider Trade•Filed: 2026-06-26
👔
Akari Therapeutics Plc
@AKTX_InsiderForm 4 Filing: Gaslightwala Abizer Acquires (Grant) shares of $AKTX
STOCK AWARD / GRANT
⚡ MATERIALITY: 2/10
corporate issuer
Akari Therapeutics Plc
Ticker: $AKTX
Transaction Value
N/A (Non-Open-Market)
Price/Share: $0.00 (Non-Open-Market)
transaction date
2026-06-24
Shares: 21,063
Market Price Activity
HillSignal AI Analytical Report
SEC Form 4 documents direct changes in beneficial ownership of securities for public corporations. The reporting insider, Gaslightwala Abizer, holds the title of CEO at Akari Therapeutics Plc.
On 2026-06-24, the insider transacted 21,063 shares.This transaction is a non-open-market event (such as a stock grant or option exercise) with a reported price per share of $0.00.
Executive Summary Summary
Gaslightwala Abizer (CEO) was granted $0 of $AKTX
Post-Transaction Position: 5,500 shares
SEC Accession No: 0001493152-26-030207 (CIK: 2049375)
Verified Multi-Source Index
Verify the accuracy of this insider transaction and corporate entity independently. HillSignal pulls data directly from official SEC databases; use the sources below to corroborate.